A 2023 review summarizes advances in cardiovascular pharmacology, including first-in-class drugs for atherosclerotic cardiovascular disease and heart failure, and drug repurposing strategies.
This review highlights the key 2023 advancements in cardiovascular pharmacology, including new drug approvals, repurposed therapies, and ongoing phase 2/3 trials for CVD and heart failure.
Although cardiovascular diseases (CVDs) are the leading cause of death worldwide, their pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more effective and safer pharmacological strategies. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2023, including the approval of first-in-class drugs that open new avenues for the treatment of atherosclerotic CVD and heart failure (HF). The new indications of drugs already marketed (repurposing) for the treatment of obstructive hypertrophic cardiomyopathy, hypercholesterolaemia, type 2 diabetes, obesity, and HF; the impact of polypharmacy on guideline-directed drug use is highlighted as well as results from negative clinical trials. Finally, we end with a summary of the most important phase 2 and 3 clinical trials assessing the efficacy and safety of cardiovascular drugs under development for the prevention and treatment of CVDs.
Tamargo et al. (Tue,) conducted a review in Cardiovascular diseases. New pharmacological agents and strategies was evaluated. A 2023 review summarizes advances in cardiovascular pharmacology, including first-in-class drugs for atherosclerotic cardiovascular disease and heart failure, and drug repurposing strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: